Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer Specialty Channel

Non-Small Cell Lung Cancer
Specialty Channel
News
FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer
10/17/2024
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA...
10/17/2024
Oncology
FDA Approval
FDA Approves Neoadjuvant/Adjuvant Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer
10/03/2024
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the...
10/03/2024
Oncology
News
FDA Approves Osimertinib Following Chemoradiation for Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer Harboring EGFR Mutations
09/25/2024
Based on results from the LAURA trial, the FDA has approved osimertinib for patients with locally advanced, unresectable non-small lung cancer harboring EGFR mutations who do not experience disease progression on or after concurrent or...
Based on results from the LAURA trial, the FDA has approved osimertinib for patients with locally advanced, unresectable non-small lung cancer harboring EGFR mutations who do not experience disease progression on or after concurrent or...
Based on results from the LAURA...
09/25/2024
Oncology
Conference Coverage
Nivolumab Sustains Clinical Benefit Among Patients With Resectable Non-Small Cell Lung Cancer
09/25/2024
According to updated results from the CheckMate 77T study, nivolumab sustained clinical benefit among patients with resectable non-small cell lung cancer.
According to updated results from the CheckMate 77T study, nivolumab sustained clinical benefit among patients with resectable non-small cell lung cancer.
According to updated results...
09/25/2024
Oncology
Conference Coverage
Belrestotug Added to Dostarlimab Demonstrates Antitumor Activity in PD-L1-High Locally Advanced or Metastatic Non-Small Cell Lung Cancer
09/16/2024
Results from the phase 2 GALAXIES Lung-201 study show the addition of belrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.
Results from the phase 2 GALAXIES Lung-201 study show the addition of belrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.
Results from the phase 2...
09/16/2024
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
Conference Coverage
Durvalumab With Chemotherapy And Novel Agents for Early-Stage, Resectable Non-Small Cell Lung Cancer
09/11/2024
The NeoCOAST-2 trial found durvalumab, single-agent platinum chemotherapy, and datopotamab deruxtecan to yield the highest pCR rate among patients with early-stage resectable non-small cell lung cancer, when compared to other combinations.
The NeoCOAST-2 trial found durvalumab, single-agent platinum chemotherapy, and datopotamab deruxtecan to yield the highest pCR rate among patients with early-stage resectable non-small cell lung cancer, when compared to other combinations.
The NeoCOAST-2 trial found...
09/11/2024
Oncology
Conference Coverage
Inhaled Corticosteroids to Reduce Radiation-Induced Pneumonitis Among Patients With Non-Small Cell Lung Cancer
09/10/2024
Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.
Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.
Results from a phase 2 study...
09/10/2024
Oncology
Conference Coverage
Neoadjuvant Nivolumab Demonstrated Promising Efficacy and Safety Among Patients With High-Risk Early Non-Small Cell Lung Cancer
09/10/2024
According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.
According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.
According to results from the...
09/10/2024
Oncology
News
FDA Approved Lazertinib Plus Amivantamab for Advanced Non-Small Cell Lung Cancer With EGFR Mutations
08/20/2024
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib...
08/20/2024
Oncology
News
FDA Grants Approval to Neoadjuvant/Adjuvant Durvalumab for Patients With Resectable Non-Small Cell Lung Cancer
08/16/2024
The FDA has approved durvalumab plus a platinum-containing regimen followed by surgery and single-agent durvalumab for adult patients with resectable non-small cell lung cancer with no known EGFR mutations or ALK rearrangements.
The FDA has approved durvalumab plus a platinum-containing regimen followed by surgery and single-agent durvalumab for adult patients with resectable non-small cell lung cancer with no known EGFR mutations or ALK rearrangements.
The FDA has approved durvalumab...
08/16/2024
Oncology

News

News
FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer
10/17/2024
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA...
10/17/2024
Oncology
FDA Approval
FDA Approves Neoadjuvant/Adjuvant Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer
10/03/2024
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the...
10/03/2024
Oncology
News
FDA Approves Osimertinib Following Chemoradiation for Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer Harboring EGFR Mutations
09/25/2024
Based on results from the LAURA trial, the FDA has approved osimertinib for patients with locally advanced, unresectable non-small lung cancer harboring EGFR mutations who do not experience disease progression on or after concurrent or...
Based on results from the LAURA trial, the FDA has approved osimertinib for patients with locally advanced, unresectable non-small lung cancer harboring EGFR mutations who do not experience disease progression on or after concurrent or...
Based on results from the LAURA...
09/25/2024
Oncology
Conference Coverage
Nivolumab Sustains Clinical Benefit Among Patients With Resectable Non-Small Cell Lung Cancer
09/25/2024
According to updated results from the CheckMate 77T study, nivolumab sustained clinical benefit among patients with resectable non-small cell lung cancer.
According to updated results from the CheckMate 77T study, nivolumab sustained clinical benefit among patients with resectable non-small cell lung cancer.
According to updated results...
09/25/2024
Oncology
Conference Coverage
Belrestotug Added to Dostarlimab Demonstrates Antitumor Activity in PD-L1-High Locally Advanced or Metastatic Non-Small Cell Lung Cancer
09/16/2024
Results from the phase 2 GALAXIES Lung-201 study show the addition of belrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.
Results from the phase 2 GALAXIES Lung-201 study show the addition of belrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.
Results from the phase 2...
09/16/2024
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
Conference Coverage
Durvalumab With Chemotherapy And Novel Agents for Early-Stage, Resectable Non-Small Cell Lung Cancer
09/11/2024
The NeoCOAST-2 trial found durvalumab, single-agent platinum chemotherapy, and datopotamab deruxtecan to yield the highest pCR rate among patients with early-stage resectable non-small cell lung cancer, when compared to other combinations.
The NeoCOAST-2 trial found durvalumab, single-agent platinum chemotherapy, and datopotamab deruxtecan to yield the highest pCR rate among patients with early-stage resectable non-small cell lung cancer, when compared to other combinations.
The NeoCOAST-2 trial found...
09/11/2024
Oncology
Conference Coverage
Inhaled Corticosteroids to Reduce Radiation-Induced Pneumonitis Among Patients With Non-Small Cell Lung Cancer
09/10/2024
Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.
Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.
Results from a phase 2 study...
09/10/2024
Oncology
Conference Coverage
Neoadjuvant Nivolumab Demonstrated Promising Efficacy and Safety Among Patients With High-Risk Early Non-Small Cell Lung Cancer
09/10/2024
According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.
According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.
According to results from the...
09/10/2024
Oncology
News
FDA Approved Lazertinib Plus Amivantamab for Advanced Non-Small Cell Lung Cancer With EGFR Mutations
08/20/2024
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib...
08/20/2024
Oncology

Interactive Features

Quiz
Lorlatinib for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer
06/13/2024
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year...
06/13/2024
Oncology
Quiz
FDA Approves Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
05/29/2024
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the...
05/29/2024
Oncology
Quiz
Amivantamab Plus Chemotherapy for Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
04/04/2024
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the...
04/04/2024
Oncology
Quiz
FDA Approves Osimertinib Plus Chemotherapy For EGFR-Mutated Advanced NSCLC
03/21/2024
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase...
03/21/2024
Oncology
Quiz
Repotrectinib for ROS1 Fusion-Positive NSCLC
02/05/2024
02/05/2024
Oncology
Quiz
Sitravatinib Plus Nivolumab for Nonsquamous NSCLC After Progression on Checkpoint Inhibitors
05/16/2023
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with...
05/16/2023
Oncology
Quiz
Pembrolizumab Plus Chemotherapy Efficacy by PD-L1 Status in Metastatic NSCLC
04/17/2023
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score...
04/17/2023
Oncology
Quiz
Treatment-Related Adverse Events With Nivolumab Plus Ipilimumab for NSCLC
04/13/2023
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus...
04/13/2023
Oncology
Quiz
First-Line Immune Checkpoint Inhibitor Monotherapy for NSCLC
02/15/2023
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to...
02/15/2023
Oncology
Quiz
Quiz: Survival Outcomes With Pembrolizumab for Nonsquamous NSCLC
01/31/2023
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did...
01/31/2023
Oncology

Recent News

News
FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer
10/17/2024
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA...
10/17/2024
Oncology
FDA Approval
FDA Approves Neoadjuvant/Adjuvant Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer
10/03/2024
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the...
10/03/2024
Oncology
News
FDA Approves Osimertinib Following Chemoradiation for Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer Harboring EGFR Mutations
09/25/2024
Based on results from the LAURA trial, the FDA has approved osimertinib for patients with locally advanced, unresectable non-small lung cancer harboring EGFR mutations who do not experience disease progression on or after concurrent or...
Based on results from the LAURA trial, the FDA has approved osimertinib for patients with locally advanced, unresectable non-small lung cancer harboring EGFR mutations who do not experience disease progression on or after concurrent or...
Based on results from the LAURA...
09/25/2024
Oncology
Conference Coverage
Nivolumab Sustains Clinical Benefit Among Patients With Resectable Non-Small Cell Lung Cancer
09/25/2024
According to updated results from the CheckMate 77T study, nivolumab sustained clinical benefit among patients with resectable non-small cell lung cancer.
According to updated results from the CheckMate 77T study, nivolumab sustained clinical benefit among patients with resectable non-small cell lung cancer.
According to updated results...
09/25/2024
Oncology
Conference Coverage
Belrestotug Added to Dostarlimab Demonstrates Antitumor Activity in PD-L1-High Locally Advanced or Metastatic Non-Small Cell Lung Cancer
09/16/2024
Results from the phase 2 GALAXIES Lung-201 study show the addition of belrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.
Results from the phase 2 GALAXIES Lung-201 study show the addition of belrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.
Results from the phase 2...
09/16/2024
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors
09/13/2024
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...
On September 12th, 2024, the US...
09/13/2024
Oncology
Conference Coverage
Inhaled Corticosteroids to Reduce Radiation-Induced Pneumonitis Among Patients With Non-Small Cell Lung Cancer
09/10/2024
Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.
Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.
Results from a phase 2 study...
09/10/2024
Oncology
Conference Coverage
Neoadjuvant Nivolumab Demonstrated Promising Efficacy and Safety Among Patients With High-Risk Early Non-Small Cell Lung Cancer
09/10/2024
According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.
According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.
According to results from the...
09/10/2024
Oncology
News
FDA Approved Lazertinib Plus Amivantamab for Advanced Non-Small Cell Lung Cancer With EGFR Mutations
08/20/2024
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib...
08/20/2024
Oncology
News
FDA Grants Approval to Neoadjuvant/Adjuvant Durvalumab for Patients With Resectable Non-Small Cell Lung Cancer
08/16/2024
The FDA has approved durvalumab plus a platinum-containing regimen followed by surgery and single-agent durvalumab for adult patients with resectable non-small cell lung cancer with no known EGFR mutations or ALK rearrangements.
The FDA has approved durvalumab plus a platinum-containing regimen followed by surgery and single-agent durvalumab for adult patients with resectable non-small cell lung cancer with no known EGFR mutations or ALK rearrangements.
The FDA has approved durvalumab...
08/16/2024
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use